SPP1 and ischemia: Therefore, administration of the anti-OPN antibody might not only minimize the deleterious effects of ischemia-induced BBB disruption but also expand the therapeutic window of rt-PA, thus allowing rt-PA to be administered to a wider spectrum of ischemic stroke patients.